Table 1.

Demographics and disease characteristics for North American subgroup

A+AVDABVD
(n = 250)(n = 247)
Subject demographics
 Sex, n (%)
  Male146 (58)148 (60)
  Female104 (42)99 (40)
 Age, mean (SD)38.2 (16)40.5 (15)
 Age categories (years)a, n (%)
  <45171 (68)162 (66)
  45–5950 (20)51 (21)
  60–6411 (4)14 (6)
  ≥6518 (7)20 (8)
 Country, n (%)
  United States214 (86)225 (91)
  Canada36 (14)22 (9)
 Race, n (%)
  White213 (85)204 (83)
  Black or African American15 (6)16 (6)
  Not reported9 (4)15 (6)
  Asian7 (3)7 (3)
  Other6 (2)5 (2)
Disease characteristics, n (%)
 Ann Arbor stage at initial diagnosis
  Stage III99 (40)115 (47)
  Stage IV150 (60)132 (53)
 IPS score
  0–150 (20)55 (22)
  2–3123 (49)119 (48)
  4–777 (31)73 (30)
 ECOG performance status
  0118 (47)118 (48)
  1121 (48)118 (48)
  211 (4)11 (4)
Extranodal involvement at initial diagnosis
  None74 (30)92 (37)
  1 site74 (30)79 (32)
  >1 site78 (31)63 (26)
B symptomsb146 (58)139 (56)
  • aAge at date of informed consent.

  • bSubjects who present with B symptoms [general malaise (fever, night sweats, weight loss, etc.)] for at least 1 visit prior to the start of study drug administration.